Phase I (PH I) Mad Refractory Solid Tumor Study

Phase 1 Completed 60 enrolled Bristol-Myers Squibb

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, effect of food, and continue exploratory research of BMS-354825 in patients with solid tumors not responding to standard treatment, or for which no effective standard treatment exists.

Timeline

Start: 2004-07
Primary completion: 2007-07
Completion: 2007-07

Publications

Background Demetri GD, Lo Russo P, MacPherson IR, Wang D, Morgan JA, Brunton VG, Paliwal P, Agrawal S, Voi M, Evans TR. Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res. 2009 Oct 1;15(19):6232-40. doi: 10.1158/1078-0432.CCR-09-0224. Epub 2009 Sep 29.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	dasatinib anhydrous	Small molecule	35 mg	Oral
Subject	dasatinib anhydrous	Small molecule	120 mg	Oral

Phase I (PH I) Mad Refractory Solid Tumor Study

Summary

Timeline

Publications

Drugs

Indications